Loading clinical trials...
Loading clinical trials...
A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)
Conditions
Interventions
TPN-101, 400 mg/day
Placebo
Locations
19
United States
University of California San Diego
La Jolla, California, United States
University of California Irvine - ALS & Neuromuscular Center
Orange, California, United States
UCSF Neurosciences Clinical Research Unit (NCRU)
San Francisco, California, United States
John Hopkins University
Baltimore, Maryland, United States
Johns Hopkins Outpatient Center
Baltimore, Maryland, United States
Massachusetts General Hospital (MGH) - Amyotrophic Lateral Sclerosis (ALS) Multidisciplinary Clinic
Boston, Massachusetts, United States
Start Date
October 1, 2021
Primary Completion Date
August 17, 2023
Completion Date
September 1, 2023
Last Updated
April 3, 2026
NCT07545473
NCT07531732
NCT07322003
NCT07414212
NCT05104710
NCT03233646
Lead Sponsor
Transposon Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions